Silence Therapeutics and its subsidiaries are primarily involved in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. Co.'s therapeutic areas are in haematology, where Co. is developing SLN124 for iron overload disorders as seen in beta-thalassemia, myelodysplastic syndrome and hereditary haemochromatosis; in cardiovascular disease where Co. is developing SLN360 to reduce cardiovascular risk by targeting Lp(a), a cardiovascular marker that, when elevated, demonstrates risk of cardiovascular events and disease; and in a range of rare or orphan diseases. The SLN stock yearly return is shown above.
The yearly return on the SLN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SLN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|